{
    "clinical_study": {
        "@rank": "30273", 
        "arm_group": [
            {
                "arm_group_label": "AGN-199201", 
                "arm_group_type": "Experimental", 
                "description": "AGN-199201 applied to the face once daily for 29 days."
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle to AGN-199201 applied to the face once daily for 29 days."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of AGN-199201 once daily compared to\n      vehicle for the treatment of persistent moderate to severe facial erythema associated with\n      rosacea."
        }, 
        "brief_title": "Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Erythema", 
            "Rosacea"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Rosacea", 
                "Erythema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Moderate to severe persistent facial erythema associated with rosacea.\n\n        Exclusion Criteria:\n\n          -  Greater than 3 inflammatory lesions on the face\n\n          -  Current treatment with monoamine oxidase (MAO) inhibitors\n\n          -  Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or\n             Sjogren's syndrome."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "440", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132117", 
            "org_study_id": "199201-005"
        }, 
        "intervention": [
            {
                "arm_group_label": "AGN-199201", 
                "description": "AGN-199201 applied to the face once daily for 29 days.", 
                "intervention_name": "AGN-199201", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "description": "Vehicle to AGN-199201 applied to the face once daily for 29 days.", 
                "intervention_name": "Vehicle to AGN-199201", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 6, 2014", 
        "link": {
            "description": "More Information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "College Station", 
                    "country": "United States", 
                    "state": "Texas"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Participants with at Least a 2-Grade Decrease from Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Day 29"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132117"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Participants with at Least a 2-Grade Decrease from Baseline on SSA Using a 5-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 29"
            }, 
            {
                "measure": "Change from Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 29"
            }, 
            {
                "measure": "Satisfaction Assessment for Rosacea Facial Redness Using a 5-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "measure": "Symptom Assessment for Rosacea Facial Redness (Skin Sensation Domain Score) Using a 5-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "measure": "Percentage of Participants with at Least a 1-Grade Decrease from Baseline on SSA Using a 5-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 1-hour 1"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}